Financials ReproCELL Incorporated

Equities

4978

JP3974770004

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-04-26 am EDT 5-day change 1st Jan Change
135 JPY -0.74% Intraday chart for ReproCELL Incorporated -1.46% -22.86%

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 17,198 26,206 29,588 18,560 20,511 12,007 - -
Enterprise Value (EV) 1 11,566 21,101 25,067 13,998 14,133 5,928 6,178 6,278
P/E ratio -27.5 x -25.7 x -36.3 x -30 x -66.6 x -44.3 x -67.5 x -587 x
Yield - - - - - - - -
Capitalization / Revenue 15.8 x 21.9 x 23 x 8.31 x 6.95 x 4.57 x 4.06 x 3.58 x
EV / Revenue 10.6 x 17.6 x 19.5 x 6.27 x 4.79 x 2.25 x 2.09 x 1.87 x
EV / EBITDA -15.9 x -25 x -25.4 x -23.8 x -80.5 x -14.8 x -20.6 x -44.8 x
EV / FCF -17,766,522 x -25,484,586 x -35,206,167 x -47,610,645 x -46,953,130 x - - -
FCF Yield -0% -0% -0% -0% -0% - - -
Price to Book 2.43 x 4.33 x 5.49 x 2.58 x 2.71 x - - -
Nbr of stocks (in thousands) 71,066 71,407 71,641 81,760 85,107 88,941 - -
Reference price 2 242.0 367.0 413.0 227.0 241.0 135.0 135.0 135.0
Announcement Date 5/14/19 7/10/20 5/12/21 5/13/22 5/12/23 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,088 1,199 1,286 2,234 2,953 2,630 2,960 3,350
EBITDA 1 -728.7 -842.7 -986.5 -587.4 -175.6 -400 -300 -140
EBIT 1 -781 -908 -1,048 -647 -356 -460 -370 -220
Operating Margin -71.78% -75.73% -81.49% -28.96% -12.06% -17.49% -12.5% -6.57%
Earnings before Tax (EBT) 1 -627 -1,015 -811 -573 -303 -260 -170 -20
Net income 1 -601 -1,016 -812 -575 -305 -260 -170 -20
Net margin -55.24% -84.74% -63.14% -25.74% -10.33% -9.89% -5.74% -0.6%
EPS 2 -8.790 -14.27 -11.38 -7.570 -3.620 -3.050 -2.000 -0.2300
Free Cash Flow -651 -828 -712 -294 -301 - - -
FCF margin -59.83% -69.06% -55.37% -13.16% -10.19% - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 5/14/19 7/10/20 5/12/21 5/13/22 5/12/23 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S1 2021 S1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4
Net sales 1 564 614 607 989 499 746 666 910 1,576 647 730 556 591 1,147 629 853.2
EBITDA - - - - - - - - - - - - - - - -
EBIT 1 -432 -502 -83 -359 -170 -118 -86 -4 -90 -117 -149 -124 -117 -241 -48 -170.7
Operating Margin -76.6% -81.76% -13.67% -36.3% -34.07% -15.82% -12.91% -0.44% -5.71% -18.08% -20.41% -22.3% -19.8% -21.01% -7.63% -20%
Earnings before Tax (EBT) -434 -365 - -201 -150 - 42 - 70 -106 - 73 - 61 -12 -
Net income -436 -365 - -201 -150 - 42 - 68 -107 - 72 - 60 -12 -
Net margin -77.3% -59.45% - -20.32% -30.06% - 6.31% - 4.31% -16.54% - 12.95% - 5.23% -1.91% -
EPS 2 -6.130 -5.130 -1.090 -2.790 -1.950 -2.830 0.5100 0.3100 0.8200 -1.290 -3.150 0.8500 -0.1400 0.7100 -0.1400 -3.620
Dividend per Share - - - - - - - - - - - - - - - -
Announcement Date 11/13/19 11/12/20 11/12/21 11/12/21 2/10/22 5/13/22 8/10/22 11/9/22 11/9/22 2/10/23 5/12/23 8/10/23 11/10/23 11/10/23 2/9/24 -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 5,632 5,105 4,521 4,562 6,378 6,079 5,829 5,729
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -651 -828 -712 -294 -301 - - -
ROE (net income / shareholders' equity) -9.1% -15.6% -14.2% -9.1% -4.1% - - -
ROA (Net income/ Total Assets) -8.9% -12.7% -12.5% -7.17% -1.45% - - -
Assets 1 6,751 8,006 6,492 8,019 21,081 - - -
Book Value Per Share 99.50 84.80 75.20 88.10 89.00 - - -
Cash Flow per Share -7.850 -13.20 -10.20 -6.820 -3.070 - - -
Capex 97 139 64 48 161 - - -
Capex / Sales 8.92% 11.59% 4.98% 2.15% 5.45% - - -
Announcement Date 5/14/19 7/10/20 5/12/21 5/13/22 5/12/23 - - -
1JPY in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
  1. Stock Market
  2. Equities
  3. 4978 Stock
  4. Financials ReproCELL Incorporated